Louisiana State Employees Retirement System Makes New Investment in LeMaitre Vascular, Inc. $LMAT

Posted by George Bondi on Jul 5th, 2026

Louisiana State Employees Retirement System bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) during the 1st quarter, Holdings Channel reports. The institutional investor bought 9,300 shares of the medical instruments supplier’s stock, valued at approximately $1,015,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Illinois Municipal Retirement Fund raised its holdings in shares of LeMaitre Vascular by 1.1% during the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 123 shares during the period. NewEdge Advisors LLC increased its position in LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after buying an additional 139 shares during the last quarter. State of Alaska Department of Revenue raised its stake in LeMaitre Vascular by 1.2% in the fourth quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after buying an additional 147 shares during the period. Federated Hermes Inc. lifted its position in shares of LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after buying an additional 155 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 32.7% in the fourth quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 179 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the completion of the transaction, the chief executive officer directly owned 1,430,019 shares in the company, valued at $155,428,765.11. This represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the sale, the director owned 3,942 shares in the company, valued at $437,956.20. This represents a 56.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is owned by insiders.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $102.88 on Friday. The firm’s 50 day simple moving average is $98.79 and its 200 day simple moving average is $97.19. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of 37.96, a P/E/G ratio of 2.86 and a beta of 0.52. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a 1 year low of $79.00 and a 1 year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. The firm had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were issued a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is 36.90%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday. Barrington Research reiterated an “outperform” rating and issued a $120.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Freedom Capital raised LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $112.60.

Read Our Latest Analysis on LMAT

LeMaitre Vascular Company Profile

(Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.